What does S&H Pharma do?

S&H Pharma is a pharmacy in Gent. Private Limited, started on 19 April 2011, 1 establishment.

What is the address of S&H Pharma?

The registered office of S&H Pharma is located at Loofblommestraat 55, 9051 Gent.

Is S&H Pharma still active?

Yes. According to the CBE (29 October 2026) S&H Pharma is active, legal situation “Normale toestand”, started on 19 April 2011.

Is S&H Pharma registered on Peppol?

Yes, S&H Pharma is registered on the Peppol network with ID 0208:0835699342.

What is the enterprise number of S&H Pharma?

The enterprise number of S&H Pharma is BE0835699342.

When was S&H Pharma founded?

S&H Pharma was founded on 19 April 2011.

Who are the directors of S&H Pharma?

According to the 2025 annual accounts, the directors of S&H Pharma are: S&H Holding BV.

Is S&H Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 April 2011; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did S&H Pharma make in 2025?

S&H Pharma posted a profit after taxes of € 55,644 in financial year 2025.

What is the revenue of S&H Pharma?

As a small company, S&H Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 256,683.

How much does an employee at S&H Pharma earn?

The average wage cost per full-time employee at S&H Pharma was € 68,100 in 2025: staff costs of € 156,741 for 2.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does S&H Pharma have?

According to the 2025 annual accounts, S&H Pharma has 2.3 full-time equivalents (FTE).

S&H Pharma (Private Limited) - Gent - BE0835699342

Dossier S&H Pharma, printed on 29 October 2026 from databakkes.be/en/0835699342/s-h-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

S&H Pharma from Gent, company number BE0835699342, closed financial year 2025 with a result of € 55,644 after tax. For that financial year S&H Pharma recorded a gross margin of € 256,683 and equity of € 320,239. Compared with financial year 2024, the result moved from € 82,922 to € 55,644. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 6, 2026.

What it is worth Growing

€ 320,239

▲ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 55,644

▼ 33% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 28,101

▼ 49% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 39,000 paid out

70 % of the profit went to the shareholders, mostly to S&H HOLDING (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

2.3

▲ 0.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 156,741

▲ 42% vs 2024

€ 68,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 44,297

▲ € 43,626 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 10 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 271,215

▲ 13% vs 2024

€ 27,284 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.

Owed to suppliers

€ 90,426

▲ 44% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 36,414

▲ 66% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 199,640 Gross margin 2022: € 199,640 First fiscal year in the series	€ 217,963 Gross margin 2023: € 217,963 ▲ 9% vs 2022 (€ 199,640) Favourable step	€ 232,902 Gross margin 2024: € 232,902 ▲ 7% vs 2023 (€ 217,963) Favourable step	€ 256,683 Gross margin 2025: € 256,683 ▲ 10% vs 2024 (€ 232,902) Favourable step	▲ 10%
Profit after taxes	€ 74,146 Profit after taxes 2022: € 74,146 First fiscal year in the series	€ 49,147 Profit after taxes 2023: € 49,147 ▼ 34% vs 2022 (€ 74,146) Unfavourable step	€ 82,922 Profit after taxes 2024: € 82,922 ▲ 69% vs 2023 (€ 49,147) Favourable step	€ 55,644 Profit after taxes 2025: € 55,644 ▼ 33% vs 2024 (€ 82,922) Unfavourable step	▼ 33%
Equity	€ 269,526 Equity 2022: € 269,526 First fiscal year in the series	€ 279,673 Equity 2023: € 279,673 ▲ 4% vs 2022 (€ 269,526) Favourable step	€ 303,595 Equity 2024: € 303,595 ▲ 9% vs 2023 (€ 279,673) Favourable step	€ 320,239 Equity 2025: € 320,239 ▲ 5% vs 2024 (€ 303,595) Favourable step	▲ 5%
Total debts	€ 438,135 Total debts 2022: € 438,135 First fiscal year in the series	€ 387,809 Total debts 2023: € 387,809 ▼ 11% vs 2022 (€ 438,135) Favourable step	€ 398,401 Total debts 2024: € 398,401 ▲ 3% vs 2023 (€ 387,809) Unfavourable step	€ 444,699 Total debts 2025: € 444,699 ▲ 12% vs 2024 (€ 398,401) Unfavourable step	▲ 12%
Cash	€ 5,601 Cash 2022: € 5,601 First fiscal year in the series	€ 33,777 Cash 2023: € 33,777 ▲ € 28,176 vs 2022 (€ 5,601) Favourable step	€ 54,998 Cash 2024: € 54,998 ▲ 63% vs 2023 (€ 33,777) Favourable step	€ 28,101 Cash 2025: € 28,101 ▼ 49% vs 2024 (€ 54,998) Unfavourable step	▼ 49%
Land & buildings	€ 302,433 Land & buildings 2022: € 302,433 First fiscal year in the series	€ 286,695 Land & buildings 2023: € 286,695 ▼ 5% vs 2022 (€ 302,433) Unchanged	€ 270,957 Land & buildings 2024: € 270,957 ▼ 5% vs 2023 (€ 286,695) Unchanged	€ 261,094 Land & buildings 2025: € 261,094 ▼ 4% vs 2024 (€ 270,957) Unchanged	▼ 4%
Retained profit	€ 190,926 Retained profit 2022: € 190,926 First fiscal year in the series	€ 201,073 Retained profit 2023: € 201,073 ▲ 5% vs 2022 (€ 190,926) Favourable step	€ 224,995 Retained profit 2024: € 224,995 ▲ 12% vs 2023 (€ 201,073) Favourable step	€ 241,639 Retained profit 2025: € 241,639 ▲ 7% vs 2024 (€ 224,995) Favourable step	▲ 7%
Dividend	€ 59,000 Dividend 2022: € 59,000 First fiscal year in the series	€ 39,000 Dividend 2023: € 39,000 ▼ 34% vs 2022 (€ 59,000) Unchanged	€ 59,000 Dividend 2024: € 59,000 ▲ 51% vs 2023 (€ 39,000) Unchanged	€ 39,000 Dividend 2025: € 39,000 ▼ 34% vs 2024 (€ 59,000) Unchanged	▼ 34%
Bank debt	€ 293,001 Bank debt 2022: € 293,001 First fiscal year in the series	€ 258,338 Bank debt 2023: € 258,338 ▼ 12% vs 2022 (€ 293,001) Favourable step	€ 239,798 Bank debt 2024: € 239,798 ▼ 7% vs 2023 (€ 258,338) Favourable step	€ 271,215 Bank debt 2025: € 271,215 ▲ 13% vs 2024 (€ 239,798) Unfavourable step	▲ 13%
Balance sheet total	€ 707,661 Balance sheet total 2022: € 707,661 First fiscal year in the series	€ 667,482 Balance sheet total 2023: € 667,482 ▼ 6% vs 2022 (€ 707,661) Unchanged	€ 701,996 Balance sheet total 2024: € 701,996 ▲ 5% vs 2023 (€ 667,482) Unchanged	€ 764,938 Balance sheet total 2025: € 764,938 ▲ 9% vs 2024 (€ 701,996) Unchanged	▲ 9%
Employees (FTE)	1.5 Employees (FTE) 2022: 1.5 First fiscal year in the series	1.9 Employees (FTE) 2023: 1.9 ▲ 0.4 vs 2022 (1.5) Unchanged	1.7 Employees (FTE) 2024: 1.7 ▼ 0.2 vs 2023 (1.9) Unchanged	2.3 Employees (FTE) 2025: 2.3 ▲ 0.6 vs 2024 (1.7) Unchanged	▲ 0.6

Key figures of S&H Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to S&H Pharma?

What happened at S&H Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 6, 2026 New annual accounts for financial year 2025: profit of € 55,644 (▼ 33% vs 2024). filed late Source: NBB ↗
2018 S&H Holding BV became a director. NBB
Apr 21, 2011 New establishment in Gent. KBO
Apr 19, 2011 Start of the company according to the CBE. KBO

In short

From € 74,146 profit in 2022 to € 55,644 profit in 2025.

Paid € 28,926 in corporate taxes since 2022.

Best year ever: 2024, with € 82,922 profit.

On average € 111,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

S&H HOLDING 100%

The stake of S&H HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

S&H Pharma

Behind S&H Pharma is S&H Holding BV. The shares are held by S&H HOLDING (100%).

Directors

According to the 2025 annual accounts

S&H Holding BV

Director · represented by Stéphanie van 't Klooster

since 2018

Shareholders

S&H HOLDING

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Loofblommestraat 55

9051 Gent

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0835.699.342
VAT number: BE 0835.699.342
Registered office: Loofblommestraat 55, 9051 Gent
Names & denominations: S&H Pharma
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 19 April 2011
Peppol: Active · Active since 27 Nov 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗